Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block
Lapatinib is a small molecule that reversibly inhibits the tyrosine kinase activity of EGFR and HER2. It is indicated in the treatment of breast carcinoma overexpressing HER2 (ErB2), in combination with capecitabine, in patients with advanced or metastatic disease, progressing after treatment with a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-06-01
|
| Series: | AboutOpen |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/159 |